PATIENT FORMS | NEWS | LINKS

Shealy Eye Laser Center
Shealy Eye Laser Center, 6036 Trier Road, Fort Wayne, Indiana. 800-644-6393.  

High Performance, High Fidelity Vision

Learn how we are safely producing high performance, high fidelity vision at the Shealy Eye Laser Center! Our goal for the majority is beyond 20/20 with a goal of 20/quality!
Perfect Pulse Technology  Hitting the target!  ►Retinal Pattern  High Performance Vision  German Technology  Now Is The Time To Check Into Laser Vision Correction!

ALLEGRETTO WAVE™
Right. From the Start.

Superior engineering. Again. Known for innovating the technological precision and performance found on the road, now German engineering has brought these same qualities to the eyes of our patients. Introducing the ALLEGRETTO WAVE™ Excimer Laser. Built with the pioneering and proven WaveLight technology, this revolutionary new laser provides a fundamental platform for precision, performance, safety and quality. A platform where the very basics are done, right from the start.

  • Performance—Superior Clinical Results
  • Safety—PerfectPulse Technology™
  • Smart Energy Control
  • Eye Tracking Technology
  • Speed
  • Wavefront Technology
  • High Performance Vision
  • Better Night Vision and Glare Control

Accuracy, Total Control; ALLEGRETTO WAVE’s revolutionary approach to laser vision correction minimizes problems associated with older generation lasers, such as night vision reduction, glare, and halos.

Superior Clinical Results; The success of the ALLEGRETTO WAVE can be directly measured by our patients’ remarkable improvement in visual acuity and low occurrence of side effects.

PerfectPulse Technology™; Smart energy control and eye tracking technology combine to provide an ultra-fast solution to laser vision correction. Innovative and redundant safeguards make ALLEGRETTO WAVE a leader in the field.

Visit Our Allegretto Wave mini-site!

More information about Allegretto Wave!

Back to the top.


Wavefront Analysis

Wavefront evaluation was performed first by Dr. Shealy at the Shealy Eye Laser Center in 2003 with the acquisition of the Optical Path Difference scanner. This scanner evaluated how the human eye processed light as it passes through all the structures of the eye. As bundles of light are processed, each structure makes its contribution to the focus of light inside of the eye. While most light rays form a distinct focus, many rays scatter and produce aberrated or distorted focus inside the eye. Wavefront analysis identified all the distorted or undistorted focusing points inside of each person’s eye.

Fritz Zernike, a Dutch scientist who won a Nobel prize in physics in 1953, developed a set of mathematical functions to describe individual wavefront measurements. These measurements, called Zernike coefficients, measure the various focal aberrations of the eye. There are 6 groups of coefficients that measure the wavefront aberrations of the eye. Groups 0-4 are clinically significant in the real world; whereas, the clinical significance of groups 5 and 6 have not yet been determined. The root mean square of the sum of these coefficients is directly related to the quality of vision, with normal values in the 0.5 to 1.0 range.

Until 2002, vision correction has been limited to the use of eyeglasses, contacts, and traditional lasers that corrected myopia, hyperopia, and astigmatism of the eye. While these corrections helped all to see better, it was not understood why there were differences in the quality of vision  for each patient. German Ophthalmologist Theo Seiler, MD, PhD discovered that these conventional laser corrections, which treated only spherical and cylindrical error, caused nighttime glare and haloes. This glare could be reduced or eliminated with “wavefront optimized laser vision correction.”  In 2002, Dr. Seiler introduced a new generation of excimer laser corneal ablation systems guided by wavefront principles called the Allegretto Wavelight Laser.

Dr. Seiler determined the average amount of spherical aberration that standard LASIK induced in a typical healthy patient and compensated for it with a modified wavefront ablation. This correction was designed to make a prolate cornea with a Q value of –0.46, to compensate for spherical or 4th order Zernicke aberrations. In the late 1990, this new wavefront optimized ablation was incorporated in the Allegretto Wavelight Excimer Laser, exhibited at the 2002 American Academy of Ophthalmology meeting in Orlando, Florida.

The Allegretto Wave Laser produces a prolate ablation correction, which means it preserves the patient’s natural corneal shape. This reduces glare, particularly at night, or has been described as producing an anti-glare treatment for night vision. Other laser platforms developed before the Allegretto Wave Laser had limited influence on night glare due to limitations in beam quality, design, and tracking. This “custom ablation” produced marginal reduction in glare in a lower range of prescriptions but with less accuracy. They required a greater percentage of retreatments and lesser percentages of high-quality vision compared with the Allegretto Laser. This was proven conclusively by group studies, conducted by Allegretto Wavelight users who had also had also used custom and older laser platforms.

It was commonly agreed by the top 400 laser surgeons in the world, that these results were attributed to a number of very unique features that characterize the Allegretto Wavelight laser system to include the following:

  1. Flying spot perfect pulse scanning delivery system

  2. Small laser spot size of 0.95mm

  3. Very rapid repetition rate of 200Hz

  4. Large effective optical zone of 7 mm or greater

  5. High frequency infrared eye-tracking system (200-600Hz)

  6. Wavefront optimized ablation profiles for treatments

The Allegretto Wavelight laser system was the first laser platform specifically designed for wavefront-optimized ablation.  It has the potential for allowing patients to gain vision over glasses or contacts. This occurs in FDA studies with a frequency of  60% for myopic (nearsighted) and 40% for hyperopic (farsighted) patients. Its superior accuracy allows patients who require reading glasses and have monovision to function without the need for bifocals or readers. In a series of 350 eyes, no patients had lost any best-corrected vision (BCVA) and two-thirds have gained vision beyond their pre-surgery vision with glasses or contact lenses. The clinical FDA studies of the Allegretto Wave Laser shows that at three months less than 0.4% of patients, or 4 patients per thousand surgeries, lost up to 2 or more lines of best corrected visual acuity. This is the most superlative advance to be seen in our FDA, since Laser vision correction was introduced several years ago. The Allegretto Wavelight laser has a higher potential for highest quality of vision and results in wow, wow, and wow vision in 97% of patients.

Visit Our Allegretto Wave mini-site!

More information about Allegretto Wave!

Back to the top.


More Information

More Allegretto Wave™ Information

We have a wealth of additional information on the Allegretto Wave™ Laser System and what it can accomplish, please explore the links below.

Published articles from other leading ophthalmologists about the Allegretto Wave™

Allegretto Wave's international success is supported by outstanding US clinical results:

  • First system to receive concurrent approval for myopia and hyperopia
  • In the US FDA clinical trials, 901 eyes were treated for myopia and 290 eyes were treated for hyperopia
  • For myopia, manifest refraction spherical equivalent predictability was 84.8% within ±0.5 D and 96.7% within 1 D at 3 months postoperatively
  • For hyperopia, manifest refraction spherical equivalent predictability was 72.3% within ±0.5 D and 90.4% within 1 D at 6 months postoperatively
  • For myopia, analysis of BSCVA change at 3 months postoperatively showed that 57.5% gained one line or more of vision, 36.3% remained unchanged, 5.7% lost one line of vision, and 0.6% lost 2 lines of vision
  • For hyperopia, analysis of BSCVA change at 6 months postoperatively showed that 41.2% gained one line or more of vision, 48.5% remained unchanged, 8.9% lost one line of vision, and 1.5% lost 2 lines of vision
  • The overall re-treatment rate for myopia was 3.6% at one year

Data displayed in graphs and charts from trial studies and the FDA

Other related articles

¬ GO BACK          CONTINUE ®


To Schedule Consultation & Treatment on Same Day
With Dr. Shealy, Give Us a Call at 1-800-644-6393 or Email Us!


Shealy Eye Laser Center
6036 Trier Road Fort Wayne, IN 46815 ♦ Tel: (260) 486-0065 or (800) 644-6393 ♦ email: shealy@shealyeye.com
Privacy PolicyTerms & Conditions/Disclaimer

DS